Definium Therapeutics (DFTX) Enterprise Value (2022 - 2026)

Definium Therapeutics (DFTX) has 5 years of Enterprise Value data on file, last reported at -$368.1 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 73.27% year-over-year to -$368.1 million in Q1 2026; TTM through Mar 2026 was -$368.1 million, a 73.27% decrease from a year earlier, with the FY2025 full-year figure at -$409.1 million, down 50.68% from the prior year.
• Enterprise Value for Q1 2026 stood at -$368.1 million, up from -$409.1 million in the prior quarter.
• Over the last five years, Enterprise Value for DFTX reached as high as -$96.7 million in Q4 2023 and fell as low as -$409.1 million in Q4 2025.
• Historically, Enterprise Value has averaged -$204.6 million across 5 years, with a median of -$194.3 million in 2025.
• Across the five-year window, Enterprise Value plunged 180.77% in 2024 and advanced 29.2% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$131.7 million in 2022, then climbed by 26.58% to -$96.7 million in 2023, then plunged by 180.77% to -$271.5 million in 2024, then sank by 50.68% to -$409.1 million in 2025, then advanced by 10.02% to -$368.1 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$368.1 million in Q1 2026, -$409.1 million in Q4 2025, and -$209.1 million in Q3 2025.